Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Sharma S, Pepin X, Cheung J, Zheng L, Wei H, Townsley D, Han D, Majewski M, Ware JA, Mann J, Munugalavadla V, Sheridan L, Patel P, Gupta A, Tomkinson H.
Sharma S, et al. Among authors: wei h.
Br J Clin Pharmacol. 2022 Oct;88(10):4573-4584. doi: 10.1111/bcp.15362. Epub 2022 May 25.
Br J Clin Pharmacol. 2022.
PMID: 35466438
Free article.
Clinical Trial.